![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
DexCom
DXCM
Collegium Pharmaceutical
COLL
Lantheus
LNTH
Cars.com
CARS
YETI Holdings
YETI
US Stock MarketDetailed Quotes
GERN Geron
- 3.570
- -0.030-0.83%
Close Jan 3 16:00 ET
- 3.590
- +0.020+0.56%
Post 20:01 ET
2.16BMarket Cap-11.16P/E (TTM)
3.680High3.540Low17.81MVolume3.630Open3.600Pre Close63.93MTurnover3.38%Turnover RatioLossP/E (Static)604.50MShares5.34052wk High7.38P/B1.88BFloat Cap1.64052wk Low--Dividend TTM527.58MShs Float75.875Historical High--Div YieldTTM3.89%Amplitude0.750Historical Low3.590Avg Price1Lot Size
Geron Stock Forum
Sign in to post a comment
$Geron (GERN.US)$ Something big is gonna happen
1
1
$Geron (GERN.US)$ Looks like have minimum 50% upside potential
1
$Geron (GERN.US)$ Geron Says Committee For Medicinal Products For Human Use Of The European Medicines Agency Has Recommended Approval Of RYTELO (Imetelstat) For Treatment Of Adult Patients With Transfusion-dependent (TD) Anemia Due To Very Low, Low Or Intermediate Risk Myelodysplastic Syndromes
Company says Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the approval of RYTELO (imetelstat) for the treat...
Company says Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the approval of RYTELO (imetelstat) for the treat...
2
2
$Geron (GERN.US)$ Reuters
3 mins ago
Geron Announces Phase 1 Findings From Two-Part Improvemf Study Presented at Ash Suggesting Tolerability of Rytelo™ (Imetelstat) in Combination With Ruxolitinib as Frontline Therapy in Patients With Myelofibrosis
3 mins ago
Geron Announces Phase 1 Findings From Two-Part Improvemf Study Presented at Ash Suggesting Tolerability of Rytelo™ (Imetelstat) in Combination With Ruxolitinib as Frontline Therapy in Patients With Myelofibrosis
2
$Geron (GERN.US)$
Almost low enough
Almost low enough
2
$Geron (GERN.US)$ Reuters· 2 mins ago
Geron Corp - Receives $250 Million at Closing, $125 Million in Debt Available
Geron Corp - Receives $250 Million at Closing, $125 Million in Debt Available
2
8
$Geron (GERN.US)$ Reuters· 1 mins ago
Royalty Pharma to Acquire Royalty Interest in Geron’s Rytelo for $125 Million
Royalty Pharma to Acquire Royalty Interest in Geron’s Rytelo for $125 Million
2
1
$Geron (GERN.US)$ Geron Corporation Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Achieved $28.2 million in RYTELO(TM) (imetelstat) net product revenue in first full quarter of sales
Received $250 million in gross proceeds from synthetic royalty and debt financings with Royalty Pharma and Pharmakon Advisors, with access to an additional $125 million in debt
Achieved $28.2 million in RYTELO(TM) (imetelstat) net product revenue in first full quarter of sales
Received $250 million in gross proceeds from synthetic royalty and debt financings with Royalty Pharma and Pharmakon Advisors, with access to an additional $125 million in debt
1
$Geron (GERN.US)$ Really wants to just chill at 4
No comment yet
102663425LV : Really.